Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 8/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028655 | 0.94 | KCNN4 (0.50) | KCNN4NPC1RAB9AMEN1MAPT | |
| Bromomethane SCHEMBL208626 | 0.83 | CYP1A2 (0.46) | KCNN4RAB9AMEN1MAPTHTT | |
| Bromomethane SCHEMBL208552 | 0.79 | CYP2C9 (0.55) | KCNN4NPC1RAB9AMEN1MAPT | |
| Bromomethane SCHEMBL4021492 | 0.79 | KCNN4 (0.47) | KCNN4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL7694323 | 0.78 | NPC1 (0.48) | KCNN4NPC1RAB9AMEN1MAPT | |
| SCHEMBL19182935 | 0.77 | MEN1 (0.47) | KCNN4NPC1RAB9AMEN1MAPT | |
| SCHEMBL11278233 | 0.77 | MEN1 (0.47) | KCNN4NPC1RAB9AMEN1MAPT | |
| SCHEMBL162450 | 0.76 | KCNN4 (0.50) | KCNN4NPC1RAB9AMEN1MAPT | |
| SCHEMBL522914 | 0.75 | CYP1A2 (0.52) | KCNN4RAB9AMEN1MAPTHTT | |
| SCHEMBL1421745 | 0.74 | APP (0.49) | KCNN4NPC1RAB9AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569581-B2 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | claimed |
| US-20050197357-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-09-08 | — | — | US | claimed |
| US-6706726-B2 | QUATERNIZED DIARYLACETOXY-SUBSTITUTED NORTROPANE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-16 | — | — | US | claimed |
| US-7569581-B2 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20050197357-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-09-08 | — | — | US | disclosed |
| US-20040087617-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-6706726-B2 | QUATERNIZED DIARYLACETOXY-SUBSTITUTED NORTROPANE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-16 | — | — | US | disclosed |
| US-20020115680-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115680-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | CHRM2, CHRM1, CHRM5 | KCNN4 1089/4885NPC1 2592/4885RAB9A 2208/4885 |
| US-20050197357-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | CHRM1, CHRM2, CHRM3 | KCNN4 636/4885NPC1 2487/4885RAB9A 2507/4885 |
| US-20040087617-A1 | Anticholinergics which may be used as medicaments as well as processes for preparing them | CHRM1, CHRM2, CHRM5 | KCNN4 925/4885NPC1 2654/4885RAB9A 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.